Manhattan Associates Wins Google Cloud Business Applications Partner of the Year Award for Supply Chain and Logistics
Manhattan Associates Inc. (NASDAQ: MANH) today announced that it has received the 2025 Google Cloud Business Applications Partner of the Year Award for Supply Chain and Logistics. This prestigious award highlights Manhattan’s role as an innovator within the Google Cloud ecosystem, its commitment to driving customer success, and its pioneering application of Agentic AI and Generative AI (GenAI) within the Manhattan Active® Suite over the past year.
“Google Cloud’s Partner Awards recognize partners who have created outsized value for customers through the delivery of innovative solutions and a high level of expertise,” said Kevin Ichhpurani, President, Global Partner Ecosystem, Google Cloud. "We're proud to announce Manhattan Associates as a 2025 Google Cloud Partner Award winner and celebrate their impact enabling customer success over the past year."
“We are honored to be recognized as Google Cloud’s 2025 Business Applications Partner of the Year Award for Supply Chain and Logistics,” said Sanjeev Siotia, executive vice president and CTO, Manhattan Associates. “This award is a testament to the deep collaboration between Manhattan and Google Cloud, as we work together to bring cutting-edge cloud infrastructure, data analytics, Agentic AI and GenAI capabilities to our joint customers. We look forward to continuing this partnership and driving the future of resilient, AI-driven supply chains and omnichannel commerce.”
At the core of Manhattan’s AI-powered innovations is Manhattan Active® Assist; an intelligent, contextual GenAI assistant designed to transform how users interact with the Manhattan Active solutions. Included with all Manhattan Active subscriptions, Manhattan Assist provides a natural language summary of how applications are currently configured and gives instant, accurate responses to questions about product functionality, API structures and more, across multiple personas, roles, and functions.
Manhattan Active® Maven is the company’s Agentic AI offering – an AI powered agent infused with order, payment, store location, and product availability information to deliver personalized, contextual customer service, akin to those delivered by human agents. Built on an Agentic AI platform and Google Gemini models, Manhattan Active Maven is easy to implement and embeds seamlessly with websites and mobile applications, deflecting customer service inquiries, while boosting customer satisfaction and loyalty.
“Manhattan Active Assist and Manhattan Active Maven showcase the real-world power of AI in supply chain and logistics, driving unprecedented levels of personalization, productivity, and cost-savings. Manhattan’s continued partnership with Google Cloud enables us to deliver scalable, resilient and innovative solutions that address the complex challenges of modern supply chain networks,” Siotia finished.
Recently, Manhattan and Google Cloud collaborated on the second edition of the Unified Commerce Benchmark—the industry's only analysis of unified commerce in specialty retail based on real-world purchases, returns, and customer interactions across digital and physical channels. The 2025 edition revealed the common attributes of the most successful retailers, tangible retail best practices, and key opportunities to enhance customer value through modernized operations.
Receive up-to-date partner news directly from Manhattan Associates here.
ABOUT MANHATTAN ASSOCIATES
Manhattan Associates is a global technology leader in supply chain and omnichannel commerce. We unite information across the enterprise, converging front-end sales with back-end supply chain execution. Our software, platform technology and unmatched experience help drive both top-line growth and bottom-line profitability for our customers.
Manhattan Associates designs, builds, and delivers leading edge cloud and on-premises solutions so that across the store, through your network or from your fulfillment centre, you are ready to reap the rewards of the omnichannel marketplace. For more information, please visit www.manh.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424833809/en/
Contacts
Press Contact:
James Canham-Ash
Manhattan Associates
jash@manh.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom